In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation

(2009) Bastien Mangeat et al.   PLoS Pathogens

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

(2008) C. Schliemann et al.   BLOOD

HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

(2008) Wei Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models

(2008) Shigeto Kawai et al.   CANCER SCIENCE

Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy

(2008) J. Marlind et al.   CLINICAL CANCER RESEARCH

Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin

(2008) N. Jouvenet et al.   JOURNAL OF VIROLOGY

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

(2008) Marta Pedretti et al.   LUNG CANCER

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

(2008) Stuart J. D. Neil et al.   NATURE

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE